Pain during topical photodynamic therapy - comparing methyl aminolevulinate (Metvix®) to aminolaevulinic acid (Ameluz®); an intra-individual clinical study

Publication date: Available online 2 August 2017
Source:Photodiagnosis and Photodynamic Therapy
Author(s): Shiva Yazdanyar, Kian Zarchi, Gregor B.E. Jemec
BackgroundActinic keratoses are often treated by photodynamic therapy. However, the main side effects of this treatment is pain during and short after illumination.ObjectivesTo evaluate, in an intra-individual study, whether the pain response differ in treatment of actinic keratoses in scalp and forhead, using branded methyl aminolevulinate (MAL) and aminolaevulinic acid (ALA).Materials and methods Patients with mild to moderate actinic keratoses on forehead and scalp were treated with methyl aminolaevulinate (MAL)-PDT and aminolaevulinic acid (ALA)-PDT on two similar areas of forehead and scalp. The pain response were measured using visual analogue scale ranging from 0 to 10 during the illumination and 30minutes after the treatment.ResultsFourteen patients completed treatment to MAL and ALA-PDT. We found no significant difference in pain intensity between MAL and ALA-PDT, neither during the treatment (p-value=1) nor 30minutes after the treatment (p-value of 0.19).ConclusionsThis intra-individual study demonstrate no significant difference between the pain response during PDT using methyl aminolevulinate and aminolaevulinic acid.



http://ift.tt/2u1OTub